Indaptus shares jump 10.67% premarket as Yun Yao-led investor group secures 37.8% stake and CEO change.

Indaptus Therapeutics surged 10.67% in premarket trading following the disclosure that Yun Yao acquired a 37.8% stake in the company through the conversion of preferred stock into common shares. The transaction, which closed on March 23, 2026, triggered a leadership change, with Junyi Dai appointed as CEO and director. The investor group, led by Yao, indicated plans to collaborate with the company on strategic and governance matters, potentially reshaping operations and value creation for shareholders. The move signals a shift in control and signals active engagement from a concentrated investor with a history of driving corporate changes.